Symbicort onset of action 1

Study identifier:SD-039-0732

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized, multicenter, placebo and active-controlled, single-dose, 4-period, crossover study to evaluate the bronchodilating effect of SYMBICORT pMDI versus Advair Diskus and Ventolin HFA.

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

Study drug

budesonide/formoterol (Symbicort), fluticasone/salmeterol (Advair Diskus), albuterol (Ventolin)

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Apr 2003

Primary Completion Date: -

Study Completion Date: 01 Sept 2003

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 budesonide/formoterol	-
Active Comparator: 2 fluticasone/salmeterol	-
Active Comparator: 3 albuterol	-

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

[email protected]

Investigators

Principal Investigator

Catherine Bonuccelli

AstraZeneca